Walleye Capital
LEGN icon

Walleye Capital’s Legend Biotech LEGN Stock Holding History

Walleye Capital’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-63,400
Closed -$1.15M – 4986
2026
Q1 		$1.15M Sell
63,400
-18,400
-22% -$351K ﹤0.01% 1945
2025
Q4 		$1.78M Buy
81,800
+61,300
+299% +$1.76M 0.01% 1970
2025
Q3 		$669K Buy
20,500
+7,100
+53% +$262K ﹤0.01% 2385
2025
Q2 		$476K Buy
13,400
+3,000
+29% +$97.2K ﹤0.01% 2682
2025
Q1 		$353K Sell
10,400
-8,100
-44% -$290K ﹤0.01% 2832
2024
Q4 		$602K Sell
18,500
-600
-3% -$24.9K ﹤0.01% 2842
2024
Q3 		$931K Sell
19,100
-57,700
-75% -$3.07M ﹤0.01% 2726
2024
Q2 		$3.4M Buy
76,800
+72,800
+1,820% +$3.36M 0.01% 1603
2024
Q1 		$224K Buy
4,000
+3,000
+300% +$181K ﹤0.01% 3900
2023
Q4 		$60.2K Sell
1,000
-2,800
-74% -$177K ﹤0.01% 4244
2023
Q3 		$255K Buy
+3,800
New +$264K ﹤0.01% 3361
2022
Q4 		– Sell
-23,400
Closed -$955K – 3434
2022
Q3 		$955K Buy
+23,400
New +$1.1M 0.02% 1016

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Walleye Capital's LEGN Position: Q2 2026 in Review

Walleye Capital sold out of Legend Biotech (LEGN) in Q2 2026, closing a stake of 235,415 shares — an estimated $4.26M sold.

Walleye Capital first reported a position in LEGN in Q1 2024 and held it in 9 quarters. The position peaked at $6.51M in Q4 2025. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Walleye Capital reported no remaining Legend Biotech position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 235,415 Legend Biotech shares in Q2 2026, an estimated $4.26M.
  • Walleye Capital first reported a position in Legend Biotech in Q1 2024 and held it in 9 quarters.
  • Walleye Capital's Legend Biotech position peaked at $6.51M in Q4 2025.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.